This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Popat, S. Articles by Houlston, R.S. Search for Related Content PubMed PubMed Citation Articles by Popat, S. Articles by Houlston, R.S.

Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis

From the Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK

Address reprint requests to Sanjay Popat, MRCP, PhD, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK; e-mail: sanjay.popat{at}icr.ac.uk

PURPOSE: A number of studies have investigated the relationship between microsatellite instability (MSI) and colorectal cancer (CRC) prognosis. Although many have reported a better survival with MSI, estimates of the hazard ratio (HR) among studies differ. To derive a more precise estimate of the prognostic significance of MSI, we have reviewed and pooled data from published studies.

METHODS: Studies stratifying survival in CRC patients by MSI status were eligible for analysis. The principal outcome measure was the HR. Data from eligible studies were pooled using standard techniques.

RESULTS: Thirty-two eligible studies reported survival in a total of 7,642 cases, including 1,277 with MSI. There was no evidence of publication bias. The combined HR estimate for overall survival associated with MSI was 0.65 (95% CI, 0.59 to 0.71; heterogeneity P = .16; I² = 20%). This benefit was maintained restricting analyses to clinical trial patients (HR = 0.69; 95% CI, 0.56 to 0.85) and patients with locally advanced CRC (HR = 0.67; 95% CI, 0.58 to 0.78). In patients treated with adjuvant fluorouracil (FU) CRCs with MSI had a better prognosis (HR = 0.72; 95% CI, 0.61 to 0.84). However, while data are limited, tumors with MSI derived no benefit from adjuvant FU (HR = 1.24; 95% CI, 0.72 to 2.14).

CONCLUSION: CRCs with MSI have a significantly better prognosis compared to those with intact mismatch repair. Additional studies are needed to further define the benefit of adjuvant chemotherapy in locally advanced tumors with MSI.

Supported by the UK Department of Health (S.P.) and grants from Cancer Research UK and the Association for International Cancer Research (R.S.H.).

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				R. A. Meguid, M. B. Slidell, C. L. Wolfgang, D. C. Chang, and N. Ahuja Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers? Ann. Surg. Oncol., September 1, 2008; 15(9): 2388 - 2394. [Abstract] [Full Text] [PDF]

				A Walther, R Houlston, and I Tomlinson Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis Gut, July 1, 2008; 57(7): 941 - 950. [Abstract] [Full Text] [PDF]

				I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806. [Abstract] [Full Text] [PDF]

				B. Pasche Familial Colorectal Cancer: A Genetics Treasure Trove for Medical Discovery JAMA, June 4, 2008; 299(21): 2564 - 2565. [Full Text] [PDF]

				A. J. French, D. J. Sargent, L. J. Burgart, N. R. Foster, B. F. Kabat, R. Goldberg, L. Shepherd, H. E. Windschitl, and S. N. Thibodeau Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3408 - 3415. [Abstract] [Full Text] [PDF]

				I Zlobec and A Lugli Prognostic and predictive factors in colorectal cancer J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569. [Abstract] [Full Text] [PDF]

				K. Imai and H. Yamamoto Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics Carcinogenesis, April 1, 2008; 29(4): 673 - 680. [Abstract] [Full Text] [PDF]

				S. Ogino and A. Goel Molecular Classification and Correlates in Colorectal Cancer J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27. [Abstract] [Full Text] [PDF]

				P. A. Newcomb, Y. Zheng, V. M. Chia, L. M. Morimoto, V. P. Doria-Rose, A. Templeton, S. N. Thibodeau, and J. D. Potter Estrogen Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women Cancer Res., August 1, 2007; 67(15): 7534 - 7539. [Abstract] [Full Text] [PDF]

				A. Malesci, L. Laghi, P. Bianchi, G. Delconte, A. Randolph, V. Torri, C. Carnaghi, R. Doci, R. Rosati, M. Montorsi, et al. Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3831 - 3839. [Abstract] [Full Text] [PDF]

				R. A. Hubner, S. Lubbe, I. Chandler, and R. S. Houlston MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer Hum. Mol. Genet., May 1, 2007; 16(9): 1072 - 1077. [Abstract] [Full Text] [PDF]

				J J L Wong, N J Hawkins, and R L Ward Colorectal cancer: a model for epigenetic tumorigenesis Gut, January 1, 2007; 56(1): 140 - 148. [Full Text] [PDF]

				J M Carethers Authors' reply. Gut, December 1, 2006; 55(12): 1819 - 1819. [Full Text] [PDF]

				R Jover, A Castells, X Llor, and M Andreu Authors' reply. Gut, December 1, 2006; 55(12): 1819 - 1820. [Full Text] [PDF]

				G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327. [Abstract] [Full Text] [PDF]

				D. E. Cohn, W. L. Frankel, K. E. Resnick, V. L. Zanagnolo, L. J. Copeland, H. Hampel, N. Kelbick, C. D. Morrison, and J. M. Fowler Improved Survival With an Intact DNA Mismatch Repair System in Endometrial Cancer. Obstet. Gynecol., November 1, 2006; 108(5): 1208 - 1215. [Abstract] [Full Text] [PDF]

				A S-Y Leong and T Y-M Leong Newer developments in immunohistology. J. Clin. Pathol., November 1, 2006; 59(11): 1117 - 1126. [Abstract] [Full Text] [PDF]

				J M Carethers Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer. Gut, June 1, 2006; 55(6): 759 - 761. [Full Text] [PDF]

				R Jover, P Zapater, A Castells, X Llor, M Andreu, J Cubiella, V Pinol, R M Xicola, L Bujanda, J M Rene, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer Gut, June 1, 2006; 55(6): 848 - 855. [Abstract] [Full Text] [PDF]

				G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367. [Abstract] [Full Text] [PDF]

				P. Benatti, R. Gafa, D. Barana, M. Marino, A. Scarselli, M. Pedroni, I. Maestri, L. Guerzoni, L. Roncucci, M. Menigatti, et al. Microsatellite Instability and Colorectal Cancer Prognosis Clin. Cancer Res., December 1, 2005; 11(23): 8332 - 8340. [Abstract] [Full Text] [PDF]